JP2016522179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522179A5 JP2016522179A5 JP2016509298A JP2016509298A JP2016522179A5 JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- tamoxifen
- derivative
- formula
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ2013308A3 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| CZPV2014-66 | 2014-01-29 | ||
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522179A JP2016522179A (ja) | 2016-07-28 |
| JP2016522179A5 true JP2016522179A5 (cg-RX-API-DMAC10.html) | 2017-04-06 |
| JP6375091B2 JP6375091B2 (ja) | 2018-08-15 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509298A Expired - Fee Related JP6375091B2 (ja) | 2013-04-24 | 2014-04-07 | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
Country Status (21)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10548318B2 (en) * | 2015-07-03 | 2020-02-04 | Bayer Cropscience Aktiengesellschaft | N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action |
| CN107709317B (zh) * | 2015-07-03 | 2021-05-11 | 拜耳作物科学股份公司 | 具有除草作用的n-(1,3,4-噁二唑-2-基)芳基甲酰胺衍生物 |
| HK1257296A1 (zh) * | 2016-07-12 | 2019-10-18 | Accutar Biotechnology Inc. | 新的化合物及其用途 |
| EP3484463B1 (en) | 2016-08-19 | 2020-02-12 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| JP6938682B2 (ja) | 2017-05-19 | 2021-09-22 | ルネラ・バイオテック・インコーポレーテッド | アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬 |
| WO2019083997A1 (en) | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING |
| CR20200238A (es) | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| US20220211728A1 (en) * | 2019-04-16 | 2022-07-07 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE130293T1 (de) * | 1990-10-01 | 1995-12-15 | Univ Texas | Tamoxifenderivate mit hoher affinität und ihre verwendung. |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| KR101003960B1 (ko) * | 2003-08-22 | 2010-12-30 | 안티포딘 파마슈티칼스, 인코포레이티드 | 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물 |
| AU2005261654A1 (en) * | 2004-07-13 | 2006-01-19 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| KR101642157B1 (ko) * | 2008-03-14 | 2016-07-22 | 스티븐 존 랄프 | 미토콘드리아로 전달되는 항암 화합물 |
| WO2010121177A2 (en) * | 2009-04-17 | 2010-10-21 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja not_active Expired - Fee Related
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 GE GEAP201813996A patent/GEAP201813996A/en unknown
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en not_active Expired - Fee Related
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375091B2 (ja) | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 | |
| JP2017518302A5 (cg-RX-API-DMAC10.html) | ||
| Tang et al. | Synthesis and biological evaluation of 2, 3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2 | |
| TW202545942A (zh) | Ｃｄｋ抑制劑 | |
| KR20140008297A (ko) | 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체 | |
| AU2022205484B2 (en) | Pyridone multiple-membered ring derivatives and use thereof | |
| JP2019519593A5 (cg-RX-API-DMAC10.html) | ||
| JP2017506640A5 (cg-RX-API-DMAC10.html) | ||
| NO20054526L (no) | Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen | |
| EP3416950A1 (en) | Max binders as myc modulators and uses thereof | |
| JP2014530181A5 (cg-RX-API-DMAC10.html) | ||
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2013523867A5 (cg-RX-API-DMAC10.html) | ||
| CA2878987C (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
| Mahindra et al. | Unravelling potential mechanisms of Piper retrofractum Vahl. bioactive compounds as cervical cancer chemopreventive agent by bioinformatic approach | |
| JP2010509306A5 (cg-RX-API-DMAC10.html) | ||
| JP2020506886A5 (cg-RX-API-DMAC10.html) | ||
| JP2019517474A5 (cg-RX-API-DMAC10.html) | ||
| JP2015534958A (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| Yu et al. | Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction | |
| Corcoran | Studies toward the synthesis of radioactive tyrosine kinase inhibitors, steroidal antiestrogens, and indoles as probes of biological systems | |
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| Kluckova et al. | 424 Role of the Ubiquinone Site of Complex II in Apoptosis Induction and Malignant Transformation | |
| Fernandez-Nogueira et al. | 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability | |
| HK1243598B (en) | Combination therapies |